Endovascular

Exemplary Cases From the LIFE-BTK Trial

Primary Outcomes of the Esprit™ BTK Drug-Eluting Resorbable Scaffold for the Treatment of Infrapopliteal Lesions: The LIFE-BTK Randomized Controlled Trial

Angiographic and Clinical Outcomes of the Thin-Strut MAGNITUDE Bioresorbable Scaffold in Patients with Below-the-Knee Arterial Disease: Early Results from the RESOLV I Trial

New BTK Bioresorbable Stent Technology: Life BTK, The MOTIV-BTK Trial and R3 Clinical Programs

Yes: There Is Always Room For Better Stents

No: Current DES Are Better Than Ever

R3 Vascular MAGNITUDE Bioresorbable Drug Eluting Scaffold

Bioresorbable Stent Technology for BTK Disease: Putting the Trials Into Perspective

Iliocaval Stenting and Reconstructions With Extreme Case Examples

New technology update for CLI : Scaffolds

Scaffolds Are Back: What's Old Is New

Role of Drug-Eluting Technologies as Definitive Therapy

Reflow Medical’s Temporary Spur DES System

MOTIV BRS (REVA Vascular)

APTITUDE PLLA BRS (R3 Vascular)

Hybrid Nano-Coating DES for BTK Disease

First Safety and Efficacy Study of the Misago Stent in Lower Extremity Endovascular Interventions via Radial Access Approach

Sustained Limus Release vs Paclitaxel DCB Treatment in Symptomatic Peripheral Artery Disease: The Limus FLOW Investigator-Initiated, Randomized Controlled Trial

Endovascular Sequestration of High-Risk Carotid Lesions Using the MicroNET-Covered Embolic Prevention Stent in Consecutive Patients With Symptoms or Signs of Carotid Stenosis-Related Cerebral Injury: An Investigator-Initiated, Intravascular, Ultrasound-Controlled, Multinational, Multispecialty Trial (CGuard OPTIMA)

Have We Gotten to the Final Word on Paclitaxel Safety?